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Abstract
Background: N-terminal-pro-brain natriuretic peptide (NT-proBNP) is elevated in gestational hypertension and
preeclampsia. This trial aimed to generate data for gestational diabetes mellitus patients, who are at risk to develop
these complications.
Methods: We have measured NT-proBNP in 223 otherwise healthy women between gestational week 24 and 32
referred to the outpatient diabetes unit in a cross-sectional study.
Results: 88 control subjects, 45 patients with indication for medical nutrition therapy (MNT) alone and 90 patients
who required insulin therapy were included. Groups of women were comparable regarding gestational week. Body
mass index before pregnancy and at blood draw was significantly higher in subjects with insulin dependent
gestational diabetes mellitus compared to MNT controlled gestational diabetes mellitus. NT-proBNP was
significantly lower in patients with insulin dependent gestational diabetes mellitus (35 ± 25 pg/ml) compared to
controls (53 ± 43 pg/ml, p = 0.012).
Conclusions: NT-proBNP is within the reference range of normal subjects in women with gestational diabetes
mellitus. Differences in body mass index, changes in glomerular filtration rate and haemodynamics may explain
lower NT-proBNP concentrations in insulin dependent gestational diabetes mellitus. A false negative interpretation
needs to be considered in these women.
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Background
Women with gestational diabetes mellitus (GDM) are at
risk to develop preeclampsia and other complications
during pregnancy [1-3]. Previously, it has been reported
that NT-proBNP is elevated in gestational hypertension
and preeclampsia [4], but no data exist in GDM
patients.
Amino-terminal pro B-type natriuretic peptide (NT-
proBNP) is co-secreted with B-type natriuretic peptide
(BNP) from the cardiac ventricle. It is increased in
response to ventricular volume expansion and pressure
overload [5,6]. The cardiovascular action of BNP
includes vasodilation, diuresis, inhibition of renin and
aldosterone production and reduction of cardiac and
vascular growth [7,8]. Beside these direct pharmacologi-
cal effects, BNP is also used as a biomarker in patients
with heart failure to assess systolic ventricular dysfunc-
tion [9].
Although NT-proBNP reference values are well estab-
lished in a healthy population, co-morbidities or altered
physiological states may influence its plasma concentra-
tion. This is of particular interest in subjects with dia-
betes who are at increased cardiovascular risk. However,
NT-proBNP reference ranges across patients with dia-
betes without acute complications are not appropriately
studied.
I nt h ep r e s e n tp r o s p e c t i v ec o h o r ts t u d y ,w eh a v e
therefore measured circulating concentrations of NT-
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evaluate if established reference ranges of this biomarker
may also be used in this population.
Methods
In a prospective cohort study, all pregnant women
between gestational week 24 and 32 referred to the out-
patient diabetes unit for the performance of an oral glu-
cose tolerance test (oGTT) were included. The study
protocol was approved by the Ethics Committee of the
Medical University of Vienna. Informed consent was
obtained and medical history taken. Inclusion criteria
comprised age ≥18 years and singleton pregnancy.
Exclusion criteria were presence of a clinically relevant
disease other than GDM and intake of concomitant
medication other than vitamin/iron supplementation.
All women with GDM received medical nutrition
therapy (MNT). Insulin substitution was initiated inde-
pendently from inclusion in the study according to cur-
rent guidelines after one week of MNT [10]. MNT was
sufficient in 45 women (MNT-GDM group) and addi-
tional insulin therapy was prescribed in 90 women
(iGDM group) in order to maintain normoglycemia
(fasting glucose < 95 and postprandial [1 h after meals]
glucose < 130 mg/dl). No oral antihyperglycemic medi-
cation was used. A control group of 88 women with
normal glucose tolerance was also included. Pregnancy
outcome was followed up until eight weeks after child-
birth, subjects with signs of any other pregnancy asso-
ciated disease were excluded.
A blood draw was performed at 8:00 in the morning
after an overnight fast of 12 hours. NT-proBNP was
analysed using an immunoassay (ELECSYS
® proBNP,




Data sets were descriptively analysed and presented as
means ± SD. For comparison of data, sets were tested
for normal distribution. To compare outcome para-
meters between groups, an analysis of variance or the
Kruskal-Wallis test were applied for parametric and
non-parametric datasets, respectively. The Spearman
correlation coefficient was calculated to analyse relation-
ships. p-values lower than 0.05 were considered statisti-
cally significant. Statistical analysis was performed with
the SPSS V14.0.1 (SPSS Inc., Chicago, Illinois, USA).
Results
223 pregnant women were included in the study.
Women with MNT-GDM or iGDM were comparable
with controls regarding gestational week. MNT-GDM
women were slightly younger than controls and iGDM
patients. Body mass index (BMI) before pregnancy and
at blood draw was significantly higher in subjects with
iGDM (26.2 ± 5 and 29.9 ± 4.8 kg/m
2)a sc o m p a r e dt o
t h o s ew i t hM N T - G D M( 2 2 . 6±3 . 9a n d2 6 . 2±3 . 9k g /
m
2; p < 0.005 and p < 0.001, respectively).
NT-proBNP was significantly lower in patients with
iGDM as compared to controls (p = 0.012, Table 1). No
differences were observed regarding haematocrit, total
protein, albumin, creatinine, urinary glucose, urinary
protein, C-reactive protein or thyroid-stimulating hor-
mone between the groups (data not shown).
There was a negative correlation between NT-proBNP
and HbA1c (r: -0.239; p: 0.004), total protein (r: -0.182;
p: 0.025), haematocrit (r: -0.194; p: 0.014) and BMI
before pregnancy (r: -0.363; p: < 0.001) and at blood
draw (r: -0.262; p: < 0.001) in a pooled analysis of all
subjects.
Discussion
The principal finding of this study is that NT-proBNP
i sn o te l e v a t e di nw o m e nw i t hG D Ma n dt h a tu p p e r
cut-off values may therefore also be applied to this
group of patients. However, in the subgroup of
women with iGDM, circulating NT-proBNP concen-
trations are lower than those seen in women with
MNT-GDM or in healthy pregnancies. It is therefore
possible that this biochemical marker of heart failure
may not be sensitive enough to detect early signals of
impaired cardiac function when similar reference
ranges are applied. This risk of a false negative inter-
pretation of laboratory results needs to be considered
in these women at risk.
Our data are at variance with other studies reporting
on higher NT-proBNP in subjects with type 2 diabetes
mellitus [11-13]. Comparison of those datasets, however,
is difficult because of the pathophysiology of long-stand-
ing diabetes as well as differences in age, renal function,
gender and metabolic control. Interestingly, the influ-
ence of age also seems to be important in type 2 dia-
betic subjects, since lower NT-proBNP concentrations
were observed in patients younger than 45 years when
compared to controls [14]. This difference, however, did
not persist in elderly subjects.
NT-proBNP was recently identified as a screening
parameter for left ventricular diastolic dysfunction by
Magnusson et al. [13]. About 50% of asymptomatic
patients with type 2 diabetes mellitus showed left ventri-
cular diastolic dysfunction. The onset of mild and severe
left ventricular diastolic dysfunction correlated with
increased NT-proBNP plasma levels. This effect was
pronounced in female patients. Risk factors, underlying
mechanisms and therapeutic options for left ventricular
diastolic dysfunction are still not clear. Therefore, the
occurrence of this pathology together with GDM should
be addressed in further research.
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gical cardiovascular changes that occur during preg-
nancy were not considered. It is known that peripheral
vascular resistance is highest at the beginning of preg-
nancy and decreases after the 24
th week of gestation
[15]. NT-proBNP is elevated in early pregnancy but
returns to pre-pregnant levels prior to the 24
th week of
gestation [16]. There is preliminary evidence from a
small study in women with GDM that left ventricular
mass may be augmented despite normal blood pressure
[17]. This indicates that cardiovascular alterations exist
in GDM which are not detected during routine
screening.
GDM patients are at an increased risk of developing
preeclampsia. NT-proBNP is know to be elevated in
subjects with mild and severe preeclampsia, probably
reflecting ventricular stress [18]. The prognostic value of
increased NT-proBNP during pregnancy for preeclamp-
sia has to be investigated in further projects. In addition,
NT-proBNP is a valuable marker in patients with estab-
lished heart disease prior to pregnancy [19]. The influ-
ence of GDM on NT-proBNP in these conditions has to
be taken into account.
Serum creatinine was not different between study
groups. However, glomerular filtration rate was not
measured directly. Therefore, an influence of renal
excretion on NT-proBNP variations in iGDM can not
be excluded. Again, these relationships may vary during
the course of pregnancies with or without GDM due to
glomerular hyperfiltration and other haemodynamic
changes.
The inverse relationship between NT-proBNP and
BMI is in agreement with previous results from obese
subjects [20] and suggests that differences in BMI
between groups might have contributed partly to the
reduction of NT-proBNP in iGDM. This study does also
support an inverse relationship between NT-proBNP
and haematocrit [21], but failed to detect an association
with C-reactive protein (r:- 0.15, p = 0.07) [22].
Conclusions
In conclusion, NT-proBNP reference ranges may be
applied to women with GDM, but borderline values in
women with insulin dependent GDM should be inter-
preted with caution and may be related to early haemo-
dynamic changes.
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